Loading clinical trials...
Loading clinical trials...
The aim of this study is to investigate the efficacy and safety of two doses (high and low) of empagliflozin as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) and insuffi...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Boehringer Ingelheim
Collaborators
NCT06513026 · Lactose Intolerance, Lactose Intolerant, and more
NCT07112339 · Diabetes Mellitus, Type 2
NCT06329375 · Diabetes Mellitus, Type 2, Food Insecurity, and more
NCT06945406 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
NCT06959901 · Obesity and Diabetes Mellitus, Type 2, Diabetes Prevention
1276.10.11036 Boehringer Ingelheim Investigational Site
Florence, Alabama
1276.10.11049 Boehringer Ingelheim Investigational Site
Jonesboro, Arkansas
1276.10.11040 Boehringer Ingelheim Investigational Site
Lomita, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions